Supernus Pharmaceuticals (SUPN) Capital Expenditures Growth (3y) (2014 - 2026)
Supernus Pharmaceuticals (SUPN) Capital Expenditures Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | 52.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.87% |
| Dec 31, 2025 | 65.60% |
| Jun 30, 2025 | 144.84% |
| Mar 31, 2025 | -15.86% |
| Dec 31, 2023 | -29.41% |
| Sep 30, 2023 | -2.53% |
| Mar 31, 2023 | -52.15% |
| Dec 31, 2022 | -27.34% |
| Jun 30, 2022 | -14.15% |
| Mar 31, 2022 | 40.96% |
| Dec 31, 2020 | -34.24% |
| Sep 30, 2020 | -27.26% |
| Mar 31, 2020 | 103.74% |
| Dec 31, 2019 | 105.05% |
| Sep 30, 2019 | -31.24% |
| Jun 30, 2019 | -57.18% |
| Mar 31, 2019 | -11.10% |
| Dec 31, 2018 | -51.93% |
| Sep 30, 2018 | -4.28% |
| Jun 30, 2018 | -46.71% |